Home Itens selecionados Provedores de dados OAI Créditos Sobre Ajuda

			Busca avançada
	Provedor de dados BJMBR (2) Autor Moreno,R.A. (2) Borges,N.C. (1) Figueiredo-Neto,A.M. (1) Fonseca,F.A. (1) França,C.N. (1) Hanna,M.M. (1) Helfenstein,T. (1) Izar,M.C. (1) Kasmas,S.H. (1) Moreira,F.T. (1) Ramos,S.C. (1) Tavares,S.M. (1) Wang,Y .P. (1) Mais... Palavra-chave Bipolar disorder (1) Campesterol (1) Desmosterol (1) Ezetimibe (1) Haloperidol (1) Mania (1) Olanzapine (1) Polysomnographic measurements (1) Sleep (1) Statin (1) Β-sitosterol (1) Mais... Tipo do documento Info:eu-repo/semantics/article (2) Ano 2012 (1) 2007 (1) País Brazil (2) Idioma Inglês (2)		Ordenar por:  Relevância Autor Título Ano Registros recuperados: 2 Primeira ... 1 ... Última Differences in synthesis and absorption of cholesterol of two effective lipid-lowering therapies BJMBR Kasmas,S.H.; Izar,M.C.; França,C.N.; Ramos,S.C.; Moreira,F.T.; Helfenstein,T.; Moreno,R.A.; Borges,N.C.; Figueiredo-Neto,A.M.; Fonseca,F.A.. Effective statin therapy is associated with a marked reduction of cardiovascular events. However, the explanation for full benefits obtained for LDL cholesterol targets by combined lipid-lowering therapy is controversial. Our study compared the effects of two equally effective lipid-lowering strategies on markers of cholesterol synthesis and absorption. A prospective, open label, randomized, parallel design study, with blinded endpoints, included 116 subjects. We compared the effects of a 12-week treatment with 40 mg rosuvastatin or the combination of 40 mg simvastatin/10 mg ezetimibe on markers of cholesterol absorption (campesterol and β-sitosterol), synthesis (desmosterol), and their ratios to cholesterol. Both therapies similarly decreased total and... Tipo: Info:eu-repo/semantics/article Palavras-chave: Campesterol; Β-sitosterol; Desmosterol; Statin; Ezetimibe. Ano: 2012 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2012001100015 A double-blind comparison of the effect of the antipsychotics haloperidol and olanzapine on sleep in mania BJMBR Moreno,R.A.; Hanna,M.M.; Tavares,S.M.; Wang,Y .P.. The effects of haloperidol and olanzapine on polysomnographic measures made in bipolar patients during manic episodes were compared. Twelve DSM-IV mania patients were randomly assigned to receive either haloperidol (mean ± SD final dosage: 5.8 ± 3.8 mg) or olanzapine (mean ± SD final dosage: 13.6 ± 6.9 mg) in a 6-week, double-blind, randomized, controlled clinical trial. One-night polysomnographic evaluation was performed before and after the haloperidol or olanzapine treatment. Psychopathology and illness severity were rated respectively with the Young Mania Rating Scale (YMRS) and the Clinical Global Impressions - Bipolar version (CGI-BP). There was a significant improvement in the YMRS and CGI-BP scores at the end of the study for both groups. Mixed... Tipo: Info:eu-repo/semantics/article Palavras-chave: Olanzapine; Haloperidol; Sleep; Mania; Bipolar disorder; Polysomnographic measurements. Ano: 2007 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2007000300011 Registros recuperados: 2 Primeira ... 1 ... Última

Empresa Brasileira de Pesquisa Agropecuária - Embrapa Todos os direitos reservados, conforme Lei n° 9.610 Política de Privacidade Área restrita		Embrapa Parque Estação Biológica - PqEB s/n° Brasília, DF - Brasil - CEP 70770-901 Fone: (61) 3448-4433 - Fax: (61) 3448-4890 / 3448-4891 SAC: https://www.embrapa.br/fale-conosco